<?xml version="1.0" encoding="UTF-8"?>
<p id="p0070">The SARS-CoV-2 3C-like proteinase was predicted to bind with atazanavir (
 <italic>K
  <sub>d</sub>
 </italic> 94.94 nM), followed by remdesivir, efavirenz, ritonavir, and other antiviral drugs that have a predicted affinity of 
 <italic>K
  <sub>d</sub>
 </italic> &gt; 100 nM potency (
 <xref rid="t0005" ref-type="table">Table 1</xref>). No other protease inhibitor antiviral drug was found in the 
 <italic>K
  <sub>d</sub>
 </italic> &lt; 1000 nM range. Although there is no real-world evidence about whether these drugs will act as predicted against COVID-19 yet, some case studies have been identified. For example, a docking study of lopinavir along with other HIV proteinase inhibitors of the CoV proteinase (PDBID 1UK3) suggests atazanavir and ritonavir, which are listed in the present prediction results, may inhibit the CoV proteinase in line with the inhibitory potency of lopinavir 
 <xref rid="b0135" ref-type="bibr">[27]</xref>. According to the prediction, viral proteinase-targeting drugs were predicted to act more favorably on the viral replication process than viral proteinase through the DTI model (
 <xref rid="t0010" ref-type="table">Table 2</xref>, 
 <xref rid="t0015" ref-type="table">Table 3</xref>, 
 <xref rid="t0020" ref-type="table">Table 4</xref>, 
 <xref rid="t0025" ref-type="table">Table 5</xref>, 
 <xref rid="t0030" ref-type="table">Table 6</xref>). The results include antiviral drugs other than proteinase inhibitors, such as guanosine analogues (e.g., acyclovir, ganciclovir, and penciclovir), reverse transcriptase inhibitors, and integrase inhibitors.
</p>
